trial

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

NCTId NCT00505973
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 24
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
24
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2007-07
Primary completion
—
Eligibility
MALE · 20 Years · 45 Years

Interventions & indications

Drugs
SCA-136

Sponsors

Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
24
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
SCA-136
drug
lead_sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia
indication
Schizophrenia
indication